An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes

Albrecht I, Kopfstein L, Strittmatter K, Schomber T, Falkevall A, CE Hagberg, Lorentz P, Jeltsch M, Alitalo K, Eriksson U, Christofori G, Pietras K (2010) Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS One 5 (11): e14109.

Arvidsson Y, Bergstrom A, Arvidsson L, Kristiansson E, Ahlman H, Nilsson O (2010) Hypoxia stimulates CXCR4 signalling in ileal carcinoids. Endocr Relat Cancer 17 (2): 303–316.

Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Borresen-Dale AL, Giaccia A, Longaker MT, Hastie T, Yang GP, van de Vijver MJ, Brown PO (2006) Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 3 (3): e47.

Corleto VD, Falconi M, Panzuto F, Milione M, De Luca O, Perri P, Cannizzaro R, Bordi C, Pederzoli P, Scarpa A, Delle Fave G (2009) Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas. Neuroendocrinology 89 (2): 223–230.

Couvelard A, O'Toole D, Turley H, Leek R, Sauvanet A, Degott C, Ruszniewski P, Belghiti J, AL Harris, Gatter K, Pezzella F (2005) Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer 92 (1): 94–101.

Dal Monte M, Cammalleri M, Martini D, Casini G, Bagnoli P (2007) Antiangiogenic role of somatostatin receptor 2 in a model of hypoxia-induced neovascularization in the retina: results from transgenic mice. Invest Ophthalmol Vis Sci 48 (8): 3480–3489.

Dimou AT, Syrigos KN, Saif MW (2010) Neuroendocrine tumors of the pancreas: what’s new. Highlights from the ‘2010 ASCO Gastrointestinal Cancers Symposium’. Orlando, FL, USA. January 22-24, 2010. JOP 11 (2): 135–138.

Ezziddin S, Logvinski T, Yong-Hing C, Ahmadzadehfar H, HP Fischer, Palmedo H, Bucerius J, MJ Reinhardt, HJ Biersack (2006) Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. J Nucl Med 47 (2): 223–233.

Giatromanolaki A, Harris AL (2001) Tumour hypoxia, hypoxia signaling pathways and hypoxia inducible factor expression in human cancer. Anticancer Res 21 (6B): 4317–4324.

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100 (1): 57–70.

Hirabayashi K, Zamboni G, Nishi T, Tanaka A, Kajiwara H, Nakamura N (2013) Histopathology of gastrointestinal neuroendocrine neoplasms. Front Oncol 3: 2.

Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC, Zee B, Mo F, Teo PM, Huang DP, Gatter KC, Johnson PJ, Harris AL (2002) Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 8 (8): 2595–2604.

Katoh R (2003) Angiogenesis in endocrine glands: special reference to the expression of vascular endothelial growth factor. Microsc Res Tech 60 (2): 181–185.

Kim HS, Lee HS, Kim WH (2011) Clinical significance of protein expression of cyclooxygenase-2 and somatostatin receptors in gastroenteropancreatic neuroendocrine tumors. Cancer Res Treat 43 (3): 181–188.

Kloppel G (2011) Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 18 (Suppl 1): S1–16.

Kuiper P, Hawinkels LJ, De Jonge-Muller ES, Biemond I, Lamers CB, Verspaget HW (2011) Angiogenic markers endoglin and vascular endothelial growth factor in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 17 (2): 219–225.

LeCouter J, Kowalski J, Foster J, Hass P, Zhang Z, Dillard-Telm L, Frantz G, Rangell L, DeGuzman L, GA Keller, Peale F, Gurney A, KJ Hillan, Ferrara N (2001) Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 412 (6850): 877–884.

Marion-Audibert AM, Barel C, Gouysse G, Dumortier J, Pilleul F, Pourreyron C, Hervieu V, Poncet G, Lombard-Bohas C, Chayvialle JA, Partensky C, Scoazec JY (2003) Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology 125 (4): 1094–1104.

Maynard MA, Ohh M (2005) Molecular targets from VHL studies into the oxygen-sensing pathway. Curr Cancer Drug Targets 5 (5): 345–356.

Mentlein R, Eichler O, Forstreuter F, Held-Feindt J (2001) Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. Int J Cancer 92 (4): 545–550.

Metz DC, Jensen RT (2008) Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 135 (5): 1469–1492.

Modlin IM, Oberg K, Chung DC, Jensen RT, De Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9 (1): 61–72.

O’Toole D, Couvelard A, Rebours V, Zappa M, Hentic O, Hammel P, Levy P, Bedossa P, Raymond E, Ruszniewski P (2010) Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors. Endocrine-Related Cancer 17 (4): 847–856.

Panzuto F, Campana D, Fazio N, MP Brizzi, Boninsegna L, Nori F, Di Meglio G, Capurso G, Scarpa A, Dogliotti L, De Braud F, Tomassetti P, Delle Fave G, Falconi M (2012) Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors. Neuroendocrinology 96 (1): 32–40.

Patel YC, Srikant CB (1997) Somatostatin receptors. Trends Endocrinol Metab 8 (10): 398–405.

Perigny M, Hammel P, Corcos O, Larochelle O, Giraud S, Richard S, Sauvanet A, Belghiti J, Ruszniewski P, Bedossa P, Couvelard A (2009) Pancreatic endocrine microadenomatosis in patients with von Hippel-Lindau disease: characterization by VHL/HIF pathway proteins expression. Am J Surg Pathol 33 (5): 739–748.

Pinato DJ, Mauri FA, Ramakrishnan R, Wahab L, Lloyd T, Sharma R (2012a) Inflammation-based prognostic indices in malignant pleural mesothelioma. J Thorac Oncol 7 (3): 587–594.

Pinato DJ, Ramachandran R, Toussi ST, Vergine M, Ngo N, Sharma R, Lloyd T, Meeran K, Palazzo F, Martin N, Khoo B, Dina R, Tan TM (2012b) Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations. Br J Cancer 108: 429–437.

Raymond E, Dahan L, JL Raoul, YJ Bang, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, JS Chen, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, DR Lu, Blanckmeister C, Chao R, Ruszniewski P (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364 (6): 501–513.

Rinke A, HH Muller, Schade-Brittinger C, KJ Klose, Barth P, Wied M, Mayer C, Aminossadati B, UF Pape, Blaker M, Harder J, Arnold C, Gress T, Arnold R (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27 (28): 4656–4663.

Ruscica M, Arvigo M, Steffani L, Ferone D, Magni P (2012) Somatostatin, somatostatin Analogs and somatostatin receptor dynamics in the biology of cancer progression. Curr Mol Med 13: 555–571.

Scoazec JY (2012) Angiogenesis in neuroendocrine tumors: therapeutic applications. Neuroendocrinology 97: 45–56.

Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K (2000) High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88 (10): 2239–2245.

Strosberg J, Gardner N, Kvols L (2009) Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology 89 (4): 471–476.

Takahashi Y, Akishima-Fukasawa Y, Kobayashi N, Sano T, Kosuge T, Nimura Y, Kanai Y, Hiraoka N (2007) Prognostic value of tumor architecture, tumor-associated vascular characteristics, and expression of angiogenic molecules in pancreatic endocrine tumors. Clin Cancer Res 13 (1): 187–196.

Terris B, JY Scoazec, Rubbia L, Bregeaud L, MS Pepper, Ruszniewski P, Belghiti J, Flejou J, Degott C (1998) Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 32 (2): 133–138.

Villaume K, Blanc M, Gouysse G, Walter T, Couderc C, Nejjari M, Vercherat C, Cordier-Bussat M, Roche C, JY Scoazec (2010) VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway. Neuroendocrinology 91 (3): 268–278.

Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB (2008) One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35 825 cases in the United States. J Clin Oncol 26 (18): 3063–3072.

Zhang J, Jia Z, Li Q, Wang L, Rashid A, Zhu Z, DB Evans, JN Vauthey, Xie K, JC Yao (2007) Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 109 (8): 1478–1486.